ASCI / Young Physician-Scientist Awards, 2024
The Young Physician-Scientist Awards (YPSA) recognize physician-scientists who are early in their first faculty appointment and have made notable achievements in their research.
About the awardee
Senthil Selvaraj, MD, MS, MA is a translational physician scientist with a primary goal of investigating metabolic modulation as a treatment paradigm in patients with heart failure employing early phase clinical trials. Dr. Selvaraj received undergraduate, graduate school, and medical school degrees from Northwestern University. At the Brigham and Women’s Hospital, he completed internal medicine residency and preventive cardiology fellowship, and served as chief medical resident. He went on to obtain further training in general cardiology as well as advanced training in cardiovascular imaging and advanced heart failure and transplant at the Hospital of the University of Pennsylvania. Currently, Dr. Selvaraj is an Assistant Professor of Medicine in the Section of Advanced Heart Failure and Transplant at Duke University Medical Center and faculty at the Duke Molecular Physiology Institute.
With master’s training in translational research, Dr. Selvaraj explores the therapeutic relevance of cardiovascular metabolism to patients with heart failure. Through early phase work, his research employs deep phenotyping to decipher metabolic mechanisms that may be leveraged for cardiovascular benefit. These studies characterize dynamic changes in exercise physiology, biomarker profiles integrating ‘omic platforms, echocardiography, arterial stiffness, metabolic molecular imaging techniques, among other modalities. More recently, this line of inquiry has explored the potential benefits of endogenous and exogenous ketogenic therapies among patients with heart failure. Dr. Selvaraj’s work is currently or recently funded by the National Institutes of Health, American Heart Association, Doris Duke Charitable Foundation, Mandel Foundation, Duke Heart Center Leadership Council, Institute for Translational Medicine and Therapeutics, American Society for Nuclear Cardiology, and the Foundation for Sarcoidosis Research.